Literature DB >> 163847

Antagonism of the antibacterial action of some penicillins by other penicillins and cephalosporins.

J F Acar, L D Sabath, P A Ruch.   

Abstract

There are many examples of two penicillins acting synergistically, usually by one competitively inhibiting beta-lactamase, thus protecting the other from inactivation. There are few reports on penicillins antagonizing each other. Eight strains of three genera (Proteus, Escherichia, Pseudomonas) isolated at Boston City Hospital or Institut Pasteur, Paris, showed antagonism of carbenicillin or ampicillin by cephaloridine, cloxacillin, or 6-aminopenicillanic acid. Broth dilution tests showed that with seven of the eight strains the minimum inhibiting concentration (MIC) of the more active antibiotic was increased by 800-6,400% by low concentrations (often one-tenth the MIC) of the antagonist, whereas higher concentrations of "antagonist" were not as antagonistic, This suggested that two or more receptor sites of action for penicillins were present; the antagonist thus blocks the antibacterial action at the more sensitive site but acts additively with the antagonized antibiotic at the less sensitive site. The possibility that the mechanism of antagonism was induction of inactivating enzymes (beta-lactamase, penicillin acylase) was studied in two strains(one Escherichia coli and one Proteus rettgeri), and two antagonists were studied in detail. With E. coli cephaloridine was a poorer inducer of beta-lactamase than were the antagonized antibiotic and 6-aminopenicillanic acid. From these organisms, the good inducers of a beta-lactamase that acted on benzylpenicillin did not induce enzymes that inactivated carbenicillin. Thus, the mechanism of antagonism was not due to beta-lactamase induction.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 163847      PMCID: PMC301771          DOI: 10.1172/JCI107950

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  SYNERGISTIC ACTIVITY OF PENICILLINS AGAINST PENICILLINASE-PRODUCING GRAM-NEGATIVE BACILLI.

Authors:  R SUTHERLAND; F R BATCHELOR
Journal:  Nature       Date:  1964-02-29       Impact factor: 49.962

2.  POTENTIATION OF PENICILLIN ACTION BY INHIBITION OF PENICILLINASE.

Authors:  J M HAMILTON-MILLER; J T SMITH; R KNOX
Journal:  Nature       Date:  1964-02-29       Impact factor: 49.962

3.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

4.  Penicillinase adaptation in Bacillus cereus; an analysis of three phases in the response of logarithmically growing cultures to induction of penicillinase formation by penicillin.

Authors:  M R POLLOCK
Journal:  Br J Exp Pathol       Date:  1952-12

5.  THE DETECTION OF PENICILLINASE-PRODUCING PROPERTIES OF MICROORGANISMS.

Authors:  J S Gots
Journal:  Science       Date:  1945-09-21       Impact factor: 47.728

6.  Synergistic combinations of penicillins in the treatment of bacteriuria.

Authors:  L D Sabath; H A Elder; C E McCall; M Finland
Journal:  N Engl J Med       Date:  1967-08-03       Impact factor: 91.245

7.  Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine.

Authors:  D J Tipper; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1965-10       Impact factor: 11.205

8.  Synergy of antibacterial substances by apparently known mechanisms.

Authors:  L D Sabath
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

9.  Cephalosporinase and penicillinase activities of a beta-lactamase from Pseudomonas pyocyanea.

Authors:  L D Sabath; M Jago; E P Abraham
Journal:  Biochem J       Date:  1965-09       Impact factor: 3.857

10.  Correlation between growth inhibition and the binding of various penicillins and cephalosporins to Staphylococcus aureus.

Authors:  J R Edwards; J T Park
Journal:  J Bacteriol       Date:  1969-08       Impact factor: 3.490

View more
  12 in total

1.  Activity of cefotiam in combination with beta-lactam antibiotics on enterobacterial hospital strains.

Authors:  R Vanhoof; J M Hubrechts; H J Nyssen; E Nulens; J Leger; N de Schepper; E Kupperberg; M L Couvreur
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

2.  Interaction of mezlocillin and cefoxitin against Proteus morganii in the granuloma pouch model.

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol       Date:  1982-08       Impact factor: 3.267

3.  Therapy with antibiotics in leukemic patients.

Authors:  J Klastersky
Journal:  Infection       Date:  1983       Impact factor: 3.553

4.  Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

5.  Antibacterial activity and beta-lactamase stability of temocillin.

Authors:  K Jules; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

Review 6.  Antibacterial therapy in patients with malignancies.

Authors:  K H Mayer; S M Opal
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  In vitro activity of moxalactam and mecillinam, singly and in combination, against multi-drug-resistant Enterobacteriaceae and Pseudomonas species.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.

Authors:  S H Zinner; J Klastersky; H Gaya; C Bernard; J C Ryff
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

9.  Effect of aztreonam in combination with azlocillin or piperacillin on Pseudomonas aeruginosa.

Authors:  D H Wu; A L Baltch; R P Smith; P E Conley
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 10.  Current guidelines on the use of antibacterial drugs in patients with malignancies.

Authors:  K H Mayer; O H DeTorres
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.